Back

Elderly patients are hyperresponsive to potent P2Y12 inhibitors

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Data-driven decisions for anticoagulant and antiplatelet therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor David Mutschlechner

Mistelbach-Gaenserndorf Hospital, Mistelbach (Austria)

7 More presentations in this session

Presentation thumbnail
Comparative discontinuation and non-bleeding side effects of Clopidogrel, Prasugrel and Ticagrelor in patients with acute coronary syndromes; a Network Meta-analysis of Randomized Controlled Trials
Doctor S. Yanko (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Anticoagulant monotherapy versus anticoagulant therapy in combination with single antiplatelet agent in patients after coronary artery bypass grafting - analysis of real-world data
Associate Professor R. Dabrowski (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Impact of procedural and patient-related risks on 1-year outcomes for patients with 1-month DAPT followed by P2Y12 inhibitor monotherapy after biodegradable-polymer drug-eluting stent implantation
Doctor R. Shimada (Yahaba, JP)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes of risk score-guided dual antiplatelet therapy in patients with acute coronary syndrome who underwent percutaneous coronary intervention
Assistant Professor D. Hyun (Kwang Ju, KR)
Abstract Slides Video
Presentation thumbnail
The comparison of short-term dual antiplatelet therapy versus standard dual antiplatelet therapy in elderly patients with coronary artery disease who underwent percutaneous coronary intervention
Doctor I. Jin (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Data-driven decisions for anticoagulant and antiplatelet therapy

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
One- and five-year mortality according to first use of ticagrelor or clopidogrel at the acute stage of myocardial infarction in elderly patients: the FAST-MI 2015 registry
thumbnail
Congress Presentation
Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction
thumbnail
Congress Presentation
Clinical and peri procedural outcomes using reduced dose prasugrel vs standard dose ticagrelor in elderly patients of acute coronary syndrome undergoing PCI

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources